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Résumé en
anglais
BACKGROUND: The objective was to examine the role of a sustained virological
response (SVR) on major adverse cardiovascular events (MACEs) in patients with
compensated hepatitis C virus (HCV) cirrhosis.
METHODS: Patients with the following criteria were enrolled in 35 French centers:
(1) biopsy-proven HCV cirrhosis; (2) Child-Pugh A; (3) positive viremia; and (4) no
prior liver complication, and then prospectively followed. All patients received HCV
treatment after inclusion. MACEs included stroke, myocardial infarction, ischemic
heart disease, heart failure, peripheral arterial disease, cardiac arrest, and
cardiovascular death. SVR, defined as negative viremia 12 weeks posttreatment, was
considered as a time-dependent covariate, and its effect on MACE occurrence was
assessed. The median follow up was 57.5 months, ending in December 2015.
RESULTS: Sixty-two of 878 (7.1%) patients presented a total of 79 MACEs. The main
predictive baseline factors of MACEs were Asian ethnic origin, history of MACEs,
arterial hypertension, diabetes mellitus, current smoking, low serum albumin level,
high total bilirubin level, and low platelet count. In multivariate analysis, SVR was
associated with a decreased risk of MACEs (hazard ratio=0.35, 95% CI 0.09-0.97,
P=.044), whereas Asian ethnic origin, arterial hypertension, smoking, and low serum
albumin level remained predictive of MACE occurrence. The 5-year survival rate was
60.1% versus 87.5% in patients who did versus those who did not present a MACE
(P<.001).
CONCLUSIONS: In patients with compensated HCV-related cirrhosis, Asian ethnic
origin, arterial hypertension, smoking, and low serum albumin are independent
predictive factors of cardiovascular events, whereas an SVR is associated with a
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